Vanguard Capital Management
CTSO icon

Vanguard Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Vanguard Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$716K Buy
1,914,063
+34,074
+2% +$18K ﹤0.01% 3650
2026
Q1 		$1.06M Buy
+1,879,989
New +$1.28M ﹤0.01% 3535

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM

Vanguard Capital Management's CTSO Position: Q2 2026 in Review

Vanguard Capital Management increased its Cytosorbents Corp (CTSO) stake by 1.8% in Q2 2026, buying an estimated $18K and bringing the position to 1,914,063 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

Vanguard Capital Management first reported a position in CTSO in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.06M in Q1 2026. 50 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

  • Vanguard Capital Management held 1,914,063 shares of Cytosorbents Corp worth $716K as of Q2 2026.
  • Vanguard Capital Management bought 34,074 Cytosorbents Corp shares in Q2 2026, an estimated $18K.
  • Cytosorbents Corp made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3650 holding.
  • Vanguard Capital Management first reported a position in Cytosorbents Corp in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Cytosorbents Corp position peaked at $1.06M in Q1 2026.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.